Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 14 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

14%

2 trials in Phase 3/4

Results Transparency

0 of 2 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

N/A

5(45.5%)

Phase 2

3(27.3%)

Phase 3

1(9.1%)

Phase 1

1(9.1%)

Phase 4

1(9.1%)

11Total

N/A(5)

Phase 2(3)

Phase 3(1)

Phase 1(1)

+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (14)

Showing 14 of 14 trials

NCT07340294Not ApplicableActive Not Recruiting

ClinicAL outComes of IntraVascular Lithotripsy Combined With Conventional Lesion Preparation in Patients With Moderate to Severe Coronary Artery Calcification

Role: collaborator

NCT07326839Not ApplicableNot Yet Recruiting

Orlistat and Weight Management for Uric Acid Control in Obese Gout: A RCT

Role: collaborator

NCT07156344Completed

Assessing Vulnerability and Outcomes of Intracranial Atherosclerotic Plaques

Role: collaborator

NCT05856344Not ApplicableCompleted

A Study for Crossability of Spherical Tip Versus Regular Noncompliant Balloon in Tortuous Coronary Artery Postdilatation

Role: collaborator

NCT06760078Phase 4Not Yet Recruiting

Tranexamic Acid with Intensive Blood Pressure Management in Ultra-Early Intracerebral Hemorrhage

Role: collaborator

NCT06506318Recruiting

A Joint Model Based on Deep Learning to Predict Multidrug-resistant Klebsiella Pneumoniae Liver Abscess

Role: collaborator

NCT02654561Phase 3Unknown

Efficacy and Safety of Unfractionated Heparin on Severe Sepsis With Suspected Disseminated Intravascular Coagulation

Role: collaborator

NCT05426811Phase 1Unknown

Regorafenib Plus Raltitrexed as Third-line Treatment in Advanced Colorectal Cancer Patients

Role: collaborator

NCT04045522Unknown

Study on Bisphosphonates Targeting Triple-negative Breast Cancer

Role: collaborator

NCT04612673Phase 2Unknown

A Phase II Study of Anti-PD-1 Antibody, Sintilimab, as Second-line Therapy for Biomarker-selected Advanced or Metastatic NSCLC

Role: collaborator

NCT04224714Not ApplicableUnknown

Clinical Study on the Correlation Between IMR（Index of Microcirculation Resistance） and FFR（Fractional Flow Reserve）

Role: lead

NCT03116555Phase 2Unknown

Apatinib Plus Irinotecan as Second-line Treatment in AGC or EGJA

Role: collaborator

NCT03732001Phase 2Unknown

A Study of Anlotinib in Combination With Docetaxel Versus Docetaxel Alone in Participants With Advanced NSCLC

Role: collaborator

NCT03155971Not ApplicableUnknown

PCB for Long De Novo Lesions of Main Coronary Arteries (D-Lesion Long Trial)

Role: lead

All 14 trials loaded